Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate Cancer epidemiology and risk Factors-A systematic review. Eur Urol. 2023;84:191–206.

Article  PubMed  Google Scholar 

Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–92.

Article  CAS  PubMed  Google Scholar 

Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

Article  PubMed  PubMed Central  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

Article  CAS  PubMed  Google Scholar 

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

Article  CAS  PubMed  Google Scholar 

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

Article  PubMed  Google Scholar 

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

Article  CAS  PubMed  Google Scholar 

Martin GA, Chen AH, Parikh K. A novel use of Olaparib for the treatment of metastatic castration-recurrent prostate Cancer. Pharmacotherapy. 2017;37:1406–14.

Article  PubMed  Google Scholar 

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.

Article  PubMed  Google Scholar 

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.

Article  CAS  PubMed  Google Scholar 

Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, et al. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47:713–20.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

Article  CAS  PubMed  Google Scholar 

Hope TA, Calais J. PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet. 2021;397:768–9.

Article  PubMed  Google Scholar 

Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. Real-World Data Analysis of Efficacy and survival after Lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate Cancer. Target Oncol. 2021;16:369–80.

Article  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging. 2022;49:1075–85.

Article  CAS  PubMed  Google Scholar 

Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-Approved Radiotherapeutical for treatment of prostate Cancer. Pharmaceuticals (Basel). 2022;15:1292.

Article  CAS  PubMed  Google Scholar 

Al-Ibraheem A. Theranostics in developing countries: addressing challenges and potentials from Training to Practice. World J Nucl Med. 2023;22:171–3.

Article  PubMed  PubMed Central  Google Scholar 

Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester H-J, et al. Early experience of Rechallenge 177Lu-PSMA Radioligand Therapy after an initial good response in patients with advanced prostate Cancer. J Nucl Med. 2019;60:644–8.

Article  CAS  PubMed  Google Scholar 

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1073–80.

Article  PubMed  Google Scholar 

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang S-P, Kong G, et al. Long-term follow-up and outcomes of Retreatment in an expanded 50-Patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate Cancer. J Nucl Med. 2020;61:857–65.

Article  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-resistant prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016;57:1170–6.

Article  CAS  PubMed  Google Scholar 

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials Working Group 3. J Clin Oncol. 2016;34:1402–18.

Article  PubMed  PubMed Central  Google Scholar 

Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, et al. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:597–610.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561–74.

Article  CAS  PubMed  Google Scholar 

Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72:73–7.

Article  PubMed  Google Scholar 

Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes. 2012;5:482.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32:92.

Article  PubMed